HUP0204156A3 - Recombinant antibodies to human interleukin-1 beta - Google Patents

Recombinant antibodies to human interleukin-1 beta

Info

Publication number
HUP0204156A3
HUP0204156A3 HU0204156A HUP0204156A HUP0204156A3 HU P0204156 A3 HUP0204156 A3 HU P0204156A3 HU 0204156 A HU0204156 A HU 0204156A HU P0204156 A HUP0204156 A HU P0204156A HU P0204156 A3 HUP0204156 A3 HU P0204156A3
Authority
HU
Hungary
Prior art keywords
beta
recombinant antibodies
human interleukin
interleukin
human
Prior art date
Application number
HU0204156A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9884137&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0204156(A3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HUP0204156A2 publication Critical patent/HUP0204156A2/hu
Publication of HUP0204156A3 publication Critical patent/HUP0204156A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
HU0204156A 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta HUP0204156A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001448.0A GB0001448D0 (en) 2000-01-21 2000-01-21 Organic compounds
PCT/EP2001/000591 WO2001053353A2 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interkleukin-1 beta

Publications (2)

Publication Number Publication Date
HUP0204156A2 HUP0204156A2 (hu) 2003-03-28
HUP0204156A3 true HUP0204156A3 (en) 2005-09-28

Family

ID=9884137

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0204156A HUP0204156A3 (en) 2000-01-21 2001-01-19 Recombinant antibodies to human interleukin-1 beta

Country Status (33)

Country Link
US (4) US20030124617A1 (hu)
EP (1) EP1248804B2 (hu)
JP (2) JP3978338B2 (hu)
KR (1) KR100697126B1 (hu)
CN (1) CN1395581B (hu)
AR (1) AR027253A1 (hu)
AT (1) ATE346868T1 (hu)
AU (1) AU772949B2 (hu)
BR (1) BR0107661A (hu)
CA (1) CA2396212C (hu)
CO (1) CO5261584A1 (hu)
CY (1) CY1107989T1 (hu)
CZ (1) CZ302738B6 (hu)
DE (1) DE60124863T3 (hu)
DK (1) DK1248804T4 (hu)
ES (1) ES2274865T5 (hu)
GB (1) GB0001448D0 (hu)
HK (1) HK1050013A1 (hu)
HU (1) HUP0204156A3 (hu)
IL (2) IL150551A0 (hu)
MX (1) MXPA02007091A (hu)
MY (1) MY155269A (hu)
NO (1) NO329816B1 (hu)
NZ (1) NZ519936A (hu)
PE (1) PE20011219A1 (hu)
PL (1) PL207642B1 (hu)
PT (1) PT1248804E (hu)
RU (1) RU2264413C2 (hu)
SI (1) SI1248804T2 (hu)
SK (1) SK288054B6 (hu)
TR (1) TR200201780T2 (hu)
WO (1) WO2001053353A2 (hu)
ZA (1) ZA200205659B (hu)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP2042518A3 (en) 2000-06-29 2009-04-08 Abbott Laboratories Dual specificity antibodies and methods of making and using
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
BR0307216A (pt) * 2002-01-28 2005-12-20 Medarex Inc Anticorpos monoclonais humanos para antìgeno de membrana especìfica de próstata (psma)
GB0303337D0 (en) 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
CA2537818A1 (en) * 2003-09-15 2005-03-31 Oklahoma Medical Research Foundation Method of using cytokine assays to diagnose, treat, and evaluate inflammatory and autoimmune diseases
NZ580828A (en) 2004-02-06 2011-09-30 Univ Massachusetts Antibodies against clostridium difficile toxin B and uses thereof
EP1851245B1 (en) * 2005-01-26 2012-10-10 Amgen Fremont Inc. Antibodies against interleukin-1 beta
PE20061324A1 (es) * 2005-04-29 2007-01-15 Centocor Inc Anticuerpos anti-il-6, composiciones, metodos y usos
PL2163562T3 (pl) * 2005-06-21 2014-03-31 Xoma Us Llc Przeciwciała wiążące IL-1 beta i ich fragmenty
EP3332807B1 (en) * 2005-10-26 2023-02-22 Novartis AG Use of anti il-1beta antibodies
PL1971366T3 (pl) * 2005-12-29 2015-01-30 Janssen Biotech Inc Ludzkie przeciwciała skierowane przeciw IL-23, kompozycje, sposoby i zastosowanie
US7943328B1 (en) 2006-03-03 2011-05-17 Prometheus Laboratories Inc. Method and system for assisting in diagnosing irritable bowel syndrome
KR20080109093A (ko) * 2006-04-14 2008-12-16 노파르티스 아게 안과 장애 치료를 위한 ｉｌ－1 항체의 용도
US20080085524A1 (en) * 2006-08-15 2008-04-10 Prometheus Laboratories Inc. Methods for diagnosing irritable bowel syndrome
CN103405768A (zh) * 2006-12-20 2013-11-27 爱克索马技术有限公司 用于治疗IL-1β相关疾病的方法
WO2008082651A2 (en) * 2006-12-29 2008-07-10 Abbott Laboratories Dual-specific il-1a/ il-1b antibodies
JP5337055B2 (ja) 2007-02-28 2013-11-06 メルク・シャープ・アンド・ドーム・コーポレーション 免疫性障害の処置のための組合せ治療
CA3080328C (en) * 2007-05-29 2022-06-21 Novartis Ag New indications for anti-il-1-beta therapy
US8637029B2 (en) 2007-12-20 2014-01-28 Xoma Technology Ltd. Methods for the treatment of gout
EP2293816B1 (en) * 2008-06-06 2012-11-07 XOMA Technology Ltd. Methods for the treatment of rheumatoid arthritis
EP2341936A4 (en) 2008-09-05 2012-07-25 Xoma Technology Ltd METHOD FOR TREATING OR PREVENTING IL-1ß-CONTAINED ILLNESSES
ES2622366T3 (es) 2009-10-26 2017-07-06 F. Hoffmann-La Roche Ag Procedimiento para la producción de una inmunoglobulina glucosilada
SG2014014724A (en) * 2010-05-07 2014-07-30 Xoma Technology Ltd METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
DE102010033565B4 (de) * 2010-07-27 2012-06-21 Tetec Tissue Engineering Technologies Ag Marker zur Bestimmung von Chondrozyten
US9516868B2 (en) 2010-08-02 2016-12-13 Regeneron Pharmaceuticals, Inc. Mice that make VL binding proteins
NZ607510A (en) * 2010-09-10 2014-10-31 Apexigen Inc Anti-il-1 beta antibodies and methods of use
KR101387377B1 (ko) 2011-02-25 2014-04-21 리제너론 파아마슈티컬스, 인크. Ａｄａｍ６ 마우스
PL3572517T3 (pl) 2011-08-05 2021-10-04 Regeneron Pharmaceuticals, Inc. Myszy z humanizowanym uniwersalnym łańcuchem lekkim
DE102011083595A1 (de) 2011-09-28 2013-03-28 Bayer Pharma AG Inhibition der Wirkung von Interleukin 1 beta zur Behandlung der Endometriose
CN104144946A (zh) 2011-12-19 2014-11-12 爱克索马美国有限责任公司 治疗痤疮的方法
RU2664181C2 (ru) 2011-12-20 2018-08-15 Регенерон Фармасьютикалз, Инк. Мыши с гуманизированной легкой цепью
RS60583B1 (sr) 2012-02-13 2020-08-31 Agency Science Tech & Res Ljudska monoklonalna antitela koja vrše neutralizaciju il-ss
NZ717848A (en) 2012-06-12 2019-03-29 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
BR112016021679A2 (pt) 2014-03-21 2018-12-04 Regeneron Pharmaceuticals, Inc. proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado.
KR20210088756A (ko) 2014-03-21 2021-07-14 리제너론 파마슈티칼스 인코포레이티드 단일 도메인 결합 단백질을 생산하는 비-인간 동물
CN107438622A (zh) 2015-03-19 2017-12-05 瑞泽恩制药公司 选择结合抗原的轻链可变区的非人动物
CN110818793A (zh) * 2018-08-14 2020-02-21 中山康方生物医药有限公司 抗IL-1β的抗体、其药物组合物及其用途
CN113395979A (zh) 2018-11-20 2021-09-14 詹森生物科技公司 用抗il-23特异性抗体治疗银屑病的安全且有效的方法
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4772685A (en) 1985-10-02 1988-09-20 Merck & Co., Inc. Immunogenic peptides of human interleukin-1 and the corresponding anti-peptide antibodies
US4935343A (en) * 1986-08-08 1990-06-19 Syntex (U.S.A.) Inc. Monoclonal antibodies for interleukin-1β
FR2640146B1 (fr) * 1988-12-08 1993-12-24 Commissariat A Energie Atomique Anticorps monoclonaux anti-interleukines 1(alpha) et 1(beta), leur procede de production et applications desdits anticorps a la detection des interleukines 1(alpha) et 1(beta) et en therapeutique
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
JP3714683B2 (ja) * 1992-07-30 2005-11-09 生化学工業株式会社 抗リウマチ剤
US5429614A (en) 1993-06-30 1995-07-04 Baxter International Inc. Drug delivery system
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
EP1248804B2 (en) 2009-12-02
TR200201780T2 (tr) 2003-01-21
EP1248804B1 (en) 2006-11-29
NO329816B1 (no) 2010-12-27
RU2002121649A (ru) 2004-03-10
US20030124617A1 (en) 2003-07-03
NO20023266L (no) 2002-08-28
DK1248804T4 (da) 2010-04-06
SI1248804T1 (sl) 2007-06-30
PL356297A1 (en) 2004-06-28
NO20023266D0 (no) 2002-07-05
DK1248804T3 (da) 2007-02-26
SK10352002A3 (sk) 2003-03-04
SK288054B6 (sk) 2013-03-01
IL150551A0 (en) 2003-02-12
PE20011219A1 (es) 2001-12-17
GB0001448D0 (en) 2000-03-08
CN1395581A (zh) 2003-02-05
MXPA02007091A (es) 2002-12-13
CZ302738B6 (cs) 2011-10-12
DE60124863D1 (de) 2007-01-11
HK1050013A1 (zh) 2003-06-06
AR027253A1 (es) 2003-03-19
ES2274865T5 (es) 2010-04-19
JP2003520595A (ja) 2003-07-08
RU2264413C2 (ru) 2005-11-20
US20110182894A1 (en) 2011-07-28
IL150551A (en) 2010-11-30
BR0107661A (pt) 2002-11-19
NZ519936A (en) 2004-02-27
DE60124863T3 (de) 2010-05-20
PT1248804E (pt) 2007-02-28
KR20020073178A (ko) 2002-09-19
CN1395581B (zh) 2010-10-13
AU3369701A (en) 2001-07-31
CO5261584A1 (es) 2003-03-31
PL207642B1 (pl) 2011-01-31
JP2007097598A (ja) 2007-04-19
US20060251660A1 (en) 2006-11-09
SI1248804T2 (sl) 2010-04-30
JP3978338B2 (ja) 2007-09-19
ATE346868T1 (de) 2006-12-15
WO2001053353A2 (en) 2001-07-26
US20090232803A1 (en) 2009-09-17
CZ20022531A3 (cs) 2002-10-16
AU772949B2 (en) 2004-05-13
KR100697126B1 (ko) 2007-03-20
ES2274865T3 (es) 2007-06-01
ZA200205659B (en) 2003-12-31
CA2396212A1 (en) 2001-07-26
DE60124863T2 (de) 2007-04-26
HUP0204156A2 (hu) 2003-03-28
CA2396212C (en) 2013-04-02
MY155269A (en) 2015-09-30
EP1248804A2 (en) 2002-10-16
WO2001053353A3 (en) 2002-04-04
US7491392B2 (en) 2009-02-17
CY1107989T1 (el) 2013-09-04

Similar Documents

Publication Publication Date Title
IL150551A0 (en) Recombinant antibodies to human interleukin-1 beta
NL300427I1 (en) Antibodies to human IL-1 beta
AU4835001A (en) Antibodies to human cd154
AU8390301A (en) Antibodies to human MCP-1
HK1203521A1 (en) Antibodies to nsulin-like growth factor receptor
EP1156924A4 (en) HIGH PERFORMANCE SUCTIONLY STRUCTURE
IL161705A0 (en) Human monoclonal antibodies to dendritic cells
IL185764A0 (en) Antibody to cytokine receptor zalpha11
EP1423432A4 (en) ANTIBODIES TO INTERLEUKIN 1 BETA (IL-1BETA)
EP1178829A4 (en) HUMAN MONOCLONAL ANTIBODY
AU7522401A (en) Non-agonistic antibodies to human gp39, compositions containing, and therapeuticuse thereof
TW450361U (en) Egg collector for parasite egg in feces
IL129273A0 (en) Antibodies to placental protein 13
GB2364057A8 (en) G protein coupled receptor
HK1046793A1 (zh) 多路複用器結構
GB0011269D0 (en) Protein over expression
AU2001245815A1 (en) Human immune response proteins
TW390150U (en) Improved structure for hair-washing chair
EP1152059A4 (en) NOVEL CYTOKINE RECEPTOR TYPE PROTEIN
TW435091U (en) Underpants with dividing structure
GB0016824D0 (en) Human monoclonal antibodies
GB0017139D0 (en) Human monoclonal antibodies
IL126245A0 (en) Antibodies to ifn-beta2/il-6 receptor
GB0004695D0 (en) Protein expression
GB0027675D0 (en) Protein Expression

Legal Events

Date Code Title Description
FC4A Lapse of provisional application due to refusal